Stockreport

Vaccinex Reports 2021 Financial Results and Provides Corporate Update

Vaccinex, Inc.  (VCNX) 
PDF Promising responses in Phase 1b segment of the open-label KEYNOTE B84 study of pepinemab with KEYTRUDA® in Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (R/ [Read more]